SUMMARY The effects of the synthetic prostaglandin 16, 16 dimethyl-E2 methyl ester (16-diMe-PGE2) and the histamine H2-receptor antagonist metiamide on the gastric mucosal barrier have been studied using the Heidenhain pouch dog model. The 16-diMe-PGE2 caused significant change in the ionic permeability of the mucosa when instilled into the pouch in a concentration of 300 ,ug/20 ml. (Wada and Ishizawa, 1970; Karim, Carter, Bhana, and Ganesan, 1973; Grossman and Konturek, 1974; Carter, Forrest, Werner, Heading, Park, and Shearman, 1974) , and these drugs are currently being evaluated in patients with peptic ulcer.
Prostaglandin E2 and several of its analogues and the histamine H2-receptor antagonists have recently been shown to be potent inhibitors of basal and stimulated gastric acid secretion (Wada and Ishizawa, 1970; Karim, Carter, Bhana, and Ganesan, 1973; Grossman and Konturek, 1974; Carter, Forrest, Werner, Heading, Park, and Shearman, 1974) , and these drugs are currently being evaluated in patients with peptic ulcer.
The following experiments were carried out to determine the effect of the synthetic prostaglandin 16, 16 dimethyl-E2 methyl ester and the histamine H2-receptor antagonist metiamide on the ionic permeability of the gastric mucosa with two questions in mind: (1) Do March 1975 periods. At the start of each period 25 ml of solution was instilled into the pouch via a short length of wide-bore polyethylene tubing passed through a rubber seal of the Gregory cannula. The fluid was then mixed thoroughly with the residual pouch fluid by repeated aspiration and reinstillation using a 30-ml syringe. A 5-ml initial sample was then withdrawn. The fluid then remained in the pouch for 30 minutes, after which time it was mixed thoroughly with the syringe and a final 5-ml sample taken. The remaining fluid was discarded, the pouch rinsed with basal solution and the next period commenced. It is difficult to empty the pouch completely before the commencement of each period and small amounts of fluid may remain in the potential dead space of the tubing leading into the cannula. Every attempt was made to ensure complete emptying but to minimize this source of error, a volume marker was added to the instillate and correction made for volume changes.
Periods 1 and 2 were used as control periods during which basal solution was instilled. The basal solution consisted of 80 m-equiv/1 of HC1 made isotonic with NaCl. Polyethylene glycol labelled with 14C (New England Nuclear) was added to act as a volume marker and 1 g of unlabelled polyethylene glycol (BDH) was also used to minimize loss of the labelled compound from surface adherence within the pouch.
Period 3 was the test period during which the instilled solution was either the basal solution or a taurocholate solution in which 20 mM sodium taurocholate (Koch-Light) The rate of H+ back diffusion is, however, significantly less marked. Bleeding from the pouch after administration of 16-diMe-PGE2 occurred in four of the six experiments. In one dog the minor bleeding persisted for two days after completion of the experiment, and six periods of pouch perfusion with the basal solution performed at 48 hours after exposure to prostaglandins in this animal showed an H+ back diffusion of 127 ± 1u-equiv/30 min and a net Na+ output of 794 ± 84 ,u-equiv/30 min (mean and SEM, n = 6). The control values for this dog were 112 ± 29 and 226 ± 28 respectively (n = 12). Thus a highly significant increase in Na+ output persisted (p < 0 001) for at least 48 hours after exposure to 16-diMe-PGE2 in this animal.
Intravenous
The Effect ofgastric secretory inhibitors on the gastric mucosal barrier 75 mg metiamide was administered intravenously before the taurocholate solution was used in an attempt to modify the damaging effect by blockade of the histamine H2-receptors. No change in the degree of barrier damage is evident.
Discussion
The results presented indicate that 16-diMe-PGE2 when given into the pouch causes disruption of the gastric mucosal barrier with a moderate but highly significant back diffusion of H+ and a large increase in the net movement of Na+ into the pouch. The dosage used (300 p,g) was of the same order as the oral dose of 20 ,ug/kg employed by Robert and Magerlein (1972) to achieve greater than 50% inhibition of histamine-stimulated gastric secretion when the compound was given to Heidenhain pouch dogs. However, the two regimes may not be strictly comparable in view of the larger surface area of the stomach in the experiments of Robert and Magerlein, the dilution effect of gastrointestinal secretions, and the possibility that some of the dose empties from the stomach before 30 minutes have elapsed. Robert and Magerlein (1972) have also shown that in the dog, intravenous injection of 0 5 pg/kg of 16-diMe-PGE2 gives highly potent inhibition of histamine-stimulated gastric secretion. However, when we gave the compound intravenously in doses of 0 5 ,ug/kg we were unable to demonstrate a change in the ionic permeability of the mucosa. The higher dosage of 2 ,ug/kg intravenously was used in an attempt to demonstrate similar changes in ionic permeability to those produced by intrapouch administration. Significantly the H+ and Na+ fluxes were not changed by this four-fold elevation of dosage. Nor did the intravenously administered 16-diMe-PGE2 result in any change in the response of the mucosa to 20 mM taurocholate solution.
Thus while 16-diMe-PGE2 causes profound inhibition when given orally or intravenously, its effects on the gastric mucosal barrier are seen only after local application. It appears highly probable that the damaging effect of intragastric 16-diMe-PGE2 reflects a specific biological action rather than the non-specific chemical effect of a fatty acid. It has been shown that short-chain fatty acids in concentrations of 100 mM can increase mucosal permeability (Davenport, 1964) but in our experiments the molar concentration of 16-diMe-PGE2 was approximately 40 ,uM. The analogue was initially dissolved in absolute alcohol (2 mg/ml) and aliquots of this stock solution were then added to the basal solution, resulting in an alcohol concentration in the test solution of 0-75% v/v. As Davenport (1967) has shown, the minimum alcohol concentration required to effect mucosal damage was between 8-2 and 14 % v/v, so that damage to the barrier in the present experiments cannot be attributed to the alcohol vehicle.
It has been suggested that prostaglandin E2 and its analogues inhibit gastric acid and pepsin secretion by a direct effect on the secretory cell (Karim et al, 1973) possibly by influencing the rate of cAMP production. However, in view of the failure of the analogue to influence the gastric mucosal barrier when given intravenously it appears unlikely that its damaging action on the gastric mucosal barrier is mediated by the same mechanism as that responsible for gastric secretory inhibition.
The findings that high doses of 16-diMe-PGE2 may disrupt the gastric mucosal barrier must be considered when assessing the therapeutic potential of the agent. It is conceivable that some of the apparent reduction in gastric secretion reported after oral use of the analogue in animals and man might have resulted from H+ loss due to back diffusion after damage to the mucosal barrier. However, the dosage used in our experiments was higher than the oral dose which investigators have found necessary to cause profound inhibition of acid output in man and marked inhibition has also been reported after intravenous injection (Karim et al, 1973; Nylander and Andersson, 1974) . It is, however, within the range of dosage under consideration, particularly, as the concentration of an orally administered agent within the stomach will depend largely on the residual volume within that stomach and thus the mucosa may be exposed to a considerable range of concentrations.
Further study of the effect of 16-diMe-PGE2 on the gastric mucosal barrier will be of interest.
Prostaglandin E2 is a hormone-like substance which may have a key role in the regulation of cellular metabolism, particularly with respect to secretory activity. In the present experiments the analogue of prostaglandin E2 has been shown to cause damage to the gastric mucosal barrier akin to that produced by a wide range of compounds used in much higher concentrations. In common with these compounds, the prostaglandin is lipid soluble and therefore easily crosses the cell membrane. It is not inconceivable that prostaglandin E2 is implicated in the disruption of the mucosal barrier by the standard barrier breakers such as bile salts and aspirin. However, minor modifications to the prostaglandin molecule can result in major alterations in biological activity and it remains to be shown whether the barrierbreaking action of 16-diMe-PGE2 is shared by the parent prostaglandin E2 and other related analogues.
When metiamide was introduced into the canine pouch there was no change in the ionic permeability.
As it is a weak base and appears to act as a receptor blocker rather than exerting any direct effect on cellular metabolism this result was expected. Of greater interest was the study of the effect of metiamide in modifying the action of sodium taurocholate, a known barrier breaker. That histamine plays some part in disruption of the gastric mucosal barrier has been suggested by the finding of increased histamine content of gastric venous blood after damage to the mucosa with 20 mM salicylic acid (Johnson and Overholt, 1967) . Histamine has been strongly implicated in the plasma protein loss and fluid production that accompany damage to the barrier (Davenport, 1966) . If histamine H2-receptors rather than the Hi-receptors were implicated in the changes in ionic permeability of the gastric mucosa after injury by taurocholate we could anticipate that a histamine H2-receptor antagonist would modify this change. As metiamide is a weak base with a pKa of 7-1 it would be in an ionized state in the acid environment of the test solution and therefore poorly absorbed into the mucosa of the pouch. Thus intravenous administration would be required to demonstrate this modifying effect. However, pretreatment of the mucosa with either local or intravenous metiamide did not appear to alter the damaging capacity of taurocholate.
It is of interest that in those experiments where metiamide was added to the pouch in association with taurocholate during period 3 there is a significant decrease in H+ back diffusion for this period. However, the buffering capacity of metiamide is such that 220 mg is capable of buffering approximately 55% of the H+ present in the solution of pH 1 2. As the rate of H+ back diffusion is related to the initial concentration (Black, Hole, and Rhodes, 1971) any buffering effect would be expected to decrease that rate. The increase in Na+ output during period 3 and the H+ back diffusion during the later periods were identical with those of the taurocholate controls. The decrease in back diffusion of H+ during period 3 is therefore felt not to represent any protective effect by metiamide on the gastric mucosal barrier but rather a consequence of buffering free H+ by metiamide, thus decreasing the concentration gradient down which back diffusion would occur. It is extremely unlikely that this mechanism could account for the changes in ionic flux observed after local instillation of microgram doses of the prostaglandin analogue, which, as an ester of an organic acid, would not be expected to act as a buffer. We thus conclude that we have been unable to demonstrate an effect of histamine H2-receptor blockade on the ionic fluxes after gastric mucosal barrier damage and feel it is unlikely that these receptors play a significant role in this process.
on the gastric mucosal barrier. 
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